Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Bradley J Monk, Jyoti Mayadev, Ana T Nunes

Registry-linked trialOpen access · goldAbstract readLetter

In one paragraph

Article in Gynecologic oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03830866 (A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.1field-weighted citation impact, top 47% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03830866 phase3completednot on this map

A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer

TypeinterventionalSponsorAstraZenecaRan2019 to 2023Enrolled770ConditionsLocally Advanced Cervical CancerArmsDurvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Influence of chemoradiation on the immune microenvironment of cervical cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Bradley J MonkDivision of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, AZ, USA.

Jyoti MayadevDirector of Gynecologic Brachytherapy, Chief, Gynecology Oncology Radiation Services, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, USA.

Ana T NunesAstraZeneca, 950 Wind River Ln, Gaithersburg, MD 20878, USA.

AstraZeneca (United States) · USThe US Oncology Network · USUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

•CALLA (NCT03830866) is a randomized, international, double-blind, placebo-controlled study.•Immunotherapy-naïve patients with adenocarcinoma or cervical carcinoma are being enrolled.•CALLA is one of the largest trials in this patient population.

Identifiers

PMID31867430

DOI10.1016/j.gore.2019.100506

PMCPMC6906726

OpenAlexW2979956863

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

NCT03830866ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.